GenMark Diagnostics’ ePlex Respiratory Pathogen Panel 2 (RP2) Receives EUA from FDA - Seite 3
The ePlex RP2 Panel has been funded in part with federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. 75A50120C00022. Visit https://www.genmarkdx.com/solutions/panels/eplex-panels/respiratory-pa ... to learn more about the ePlex RP2 Panel.
About Emergency Use Authorization Status
The GenMark ePlex RP2 Panel has been made available under an emergency access mechanism called an Emergency Use Authorization (EUA). The EUA is supported by the Secretary of Health and Human
Service’s (HHS’s) declaration that circumstances exist to justify the use of in vitro diagnostics (IVDs) under EUA for the detection and/or diagnosis of COVID-19. An IVD made available
under an EUA has not undergone the same type of review as an FDA cleared IVD. However, based on the totality of scientific evidence available, it is reasonable to believe that this IVD may be
effective in the detection of COVID-19. The EUA for this test is in effect for the duration of the COVID-19 emergency, unless terminated or revoked (after which the test may no longer be used). An
FDA cleared IVD should be used instead of an IVD under EUA, when applicable and available.
About GenMark Diagnostics
GenMark Diagnostics (NASDAQ: GNMK) is a leading provider of multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics, and reduce the total
cost-of-care. Utilizing GenMark’s proprietary eSensor detection technology, GenMark’s XT-8 and ePlex systems are designed to support a broad range of molecular diagnostic tests with compact,
easy-to-use workstations and self-contained, disposable test cartridges. GenMark’s ePlex System: The True Sample-to-Answer Solution is designed to optimize laboratory efficiency and address a broad
range of infectious disease testing needs, including respiratory, bloodstream and gastrointestinal infections. For more information, visit www.genmarkdx.com.
Lesen Sie auch
Forward-Looking Statements
This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements are
subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include, but are not limited to, our
ability to successfully obtain full IVD clearance of our ePlex EUA tests from the FDA and demonstrate their clinical performance and utility, the continued progression of the associated public
health emergency and associated diagnostic testing demand, our ability to satisfy the supply demands of our customers, and other risks and uncertainties described under the “Risk Factors” in our
public filings with the Securities and Exchange Commission. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the
date they are made.